Psychedelics biotech to enter clinic in Canada; Months after emerging from stealth, Walking Fish closes Series A
A Canadian company focused on psychedelic-inspired mental health treatment is collaborating with the University of Calgary in a clinical trial for a candidate that treats cancer-related distress.
The university’s Hotchkiss Brain Institute and Enveric Biosciences will team up to establish a trial of EVM-101. About 50% of cancer patients report psychological distress, such as depression, anxiety and stress-induced clinical manifestations, the company said in a release. Up to 40% of those patients meet the criteria for a mood disorder that requires treatment, and CRD has no approved treatment.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
